INO-4800 DNA Coronavirus Vaccine

INO-4800 DNA Coronavirus Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.

INO-4800 DNA Coronavirus Vaccine is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 DNA Coronavirus Vaccine results in the expression of S protein by human cells. Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 DNA Coronavirus Vaccine to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.

A Phase 1 clinical trial for INO-4800 DNA Coronavirus Vaccine in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.

Trade Name	INO-4800 DNA Coronavirus Vaccine
Generic	INO-4800
INO-4800 Other Names	INO-4800 DNA Coronavirus Vaccine
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here INO-4800 DNA Coronavirus Vaccine